The world's largest vaccine maker is producing 40 million units of a coronavirus vaccine on trial in Oxford, without yet knowing if it works
Advertisement
Bill Bostock
Apr 27, 2020, 15:55 IST
Dr Elisa Granato (left) is the first human to receive a dose of the hAdOx1 nCoV-19 vaccine from the Oxford Vaccine Group.YouTube/University of Oxford
The Serum Institute of India said it is going to start making a still-experimental coronavirus vaccine while it is still on trial.
The Oxford Vaccine Group is currently running human trials on the hAdOx1 nCoV-19 vaccine, but won't be done until September. There is no guarantee it will work.
Human trials started in Oxford on Thursday. The group is targeting September for an effective product — but there is no guarantee it will work.
Serum Institute CEO Adar Poonawalla said on Monday: "The decision — at our own risk and cost — has been solely taken to get a jump-start on manufacturing."
The world's largest vaccine maker is mass-producing a coronavirus vaccine developed by the University Oxford without knowing if it works.
The Serum Institute of India — which produces 1.5 billion vaccine doses each year for an array of diseases — said it will start production before the autumn target date of the Oxford trial.
The Oxford Vaccine Group says it hopes to complete human trials on the hAdOx1 nCoV-19 vaccine in September.
"We may get enough data in a couple of months to see if the vaccine works, but if transmission levels drop, this could take up to six months," the group said on Thursday.
Advertisement
The group hopes to produce one million doses of the vaccine itself by September.
The Serum Bio-Pharma Park in Pune, India.Serum Institute
But Adar Poonawalla, CEO of Serum Institute of India told the Times of India on Monday that he would not wait that long.
He said the institute would produce five million units of the vaccine a month, for six months, to get ahead of demand.
"We are not waiting for the trials to get over in September in UK, and then start production here. The decision — at our own risk and cost — has been solely taken to get a jump-start on manufacturing, to have enough doses available, if the clinical trials prove successful," he said.
Advertisement
Prince Charles visits the Serum Institute in November 2013 in Pune, India.Arthur Edwards - Pool/Getty Images
"We aim to manufacture four to five million doses per month for the first six months, following which, we might scale up to 10 million doses per month, based on the success of trials. We are looking to build it up to 20-40 million doses by September-October."
"We are planning to make the vaccine available at an affordable price of around 1,000 rupees ($13) in India," he said. Drug prices vary widely around the world, and the same treatment often costs many times more in other countries.
NewsletterSIMPLY PUT - where we join the dots to inform and inspire you. Sign up for a weekly brief collating many news items into one untangled thought delivered straight to your mailbox.